The stock of Ceapro Inc. (CVE:CZO) is a huge mover today! About 68,711 shares traded hands. Ceapro Inc. (CVE:CZO) has risen 6.00% since October 12, 2016 and is uptrending. It has underperformed by 0.15% the S&P500.
The move comes after 6 months negative chart setup for the $115.62 million company. It was reported on Nov, 11 by Barchart.com. We have $1.40 PT which if reached, will make CVE:CZO worth $11.56M less.
More notable recent Ceapro Inc. (CVE:CZO) news were published by: Seekingalpha.com which released: “Ceapro: A Small, Profitable, Fast-Growing Biotechnology Company” on November 04, 2016, also Marketwired.com with their article: “Ceapro Inc. Announces the Grand Opening of New Bio-processing Extraction Facility” published on September 28, 2016, Marketwired.com published: “Ceapro Inc. Reports Second Quarter 2016 Financial and Operational Results” on August 24, 2016. More interesting news about Ceapro Inc. (CVE:CZO) were released by: Marketwired.com and their article: “Ceapro Inc. Provides 2015 Business Highlights and 2016 Business Outlook” published on April 18, 2016 as well as Marketwired.com‘s news article titled: “Ceapro Inc. Presents Its PGX Technology at the 15th European Meeting on …” with publication date: May 09, 2016.
Ceapro Inc. is a Canada-based growth-stage biotechnology company. The company has a market cap of $115.62 million. The Company’s primary business activities relate to the development and commercialization of natural products for personal care, cosmetic, human and animal health industries using technology, natural and renewable resources. It has a 12.97 P/E ratio. The Company’s products include a commercial line of natural active ingredients, including beta glucan, avenanthramides , oat powder, oat oil, oat peptides and lupin peptides, which are marketed to the personal care, cosmetic, medical and animal health industries, and Veterinary therapeutic products, including an oat shampoo, an ear cleanser and a dermal complex/conditioner, which are manufactured and marketed to veterinarians in Japan and Asia.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.